Philogen SpAMIL:PHIL -0.21%62 Altman Z-Score is 13.34 as of Jun. 27, 2026, which is 0% below its 10-year median of 13.36. GuruFocus rates MIL:PHIL with a GF Score™ of 62/100 and a GF Value™ of €227.22 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 934 Biotechnology companies, Philogen SpA ranks better than 81.91% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 13.26 is strong.
Philogen SpA has a Altman Z-Score of 13.34, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Philogen SpA's Altman Z-Score or its related term are showing as below:
MIL:PHIL'
s Altman Z-Score Range Over the Past 10 Years
Min: 12.92 Med: 13.36 Max: 18.23
Current: 13.26
During the past 6 years, Philogen SpA's highest Altman Z-Score was 18.23. The lowest was 12.92. And the median was 13.36.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Philogen SpA Altman Z-Score Related Terms
Philogen SpA Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Philogen SpA's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHIL vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Philogen SpA's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Philogen SpA's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Philogen SpA's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.7925
+
1.4
*
0.6095
+
3.3
*
0.5956
+
0.6
*
14.7456
+
1.0
*
0.7187
=
13.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Philogen SpA (MIL:PHIL) has a Altman Z-Score of 13.34 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Philogen SpA and its competitors. This is near median its historical median of 13.36. Over the past decade, Philogen SpA's Altman Z-Score has ranged from 12.92 to 18.23. According to the industry distribution chart, Philogen SpA ranks #169 out of 934 companies in the Biotechnology industry, placing it in the top 18.1%.
Is Philogen SpA's Altman Z-Score too high?
Philogen SpA's current Altman Z-Score of 13.34 is near median its 10-year median of 13.36. Over the past 10 years, this metric has ranged from a low of 12.92 to a high of 18.23. The Biotechnology industry median Altman Z-Score is 2.63. Philogen SpA's value of 13.34 is 408.2% above this industry median. Based on the distribution chart, Philogen SpA ranks #169 out of 934 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Philogen SpA has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #169 out of 934 companies for Altman Z-Score. This places Philogen SpA in the top 18% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.63. Philogen SpA's value of 13.34 is 408.2% above this benchmark. Historically, Philogen SpA's own Altman Z-Score has ranged from 12.92 to 18.23 over the past decade. While the company's 10-year median is 13.36 vs. the industry median of 2.63, Philogen SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.63, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Philogen SpA's current Altman Z-Score of 13.34 is 408.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Philogen SpA and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Philogen SpA's current Altman Z-Score is 13.34, which is near median its own 10-year median of 13.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.22, compared to a current price of €23.25 — trading 89.8% below its estimated fair value. The current Altman Z-Score is 13.34, which is near median its 10-year median of 13.36 and 408.2% above the Biotechnology industry median of 2.63. Philogen SpA's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Altman Z-Score is 13.34 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €23.25 is trading 89.8% below its estimated GF Value™ of €227.22.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
Altman Z-Score: 13.34 (near median its 10-year median of 13.36)
GF Value™: €227.22 vs. price of €23.25 (89.8% below fair value)
Industry Position: 408.2% above the Biotechnology median (#169 of 934)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
62GF Score
Get the complete analysis for MIL:PHIL
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
